Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT00372073. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase IIb Randomized Study of Oral Seliciclib in Patients With Previously Treated Non-Small Cell Lung Cancer
Study identification
- NCT ID
- NCT00372073
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Cyclacel Pharmaceuticals, Inc.
- Industry
- Enrollment
- 187 participants
Conditions and interventions
Conditions
Interventions
- seliciclib Drug
- placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 8, 2006
- Primary completion
- Mar 2, 2009
- Completion
- Apr 6, 2009
- Last update posted
- Dec 21, 2021
2006 – 2009
United States locations
- U.S. sites
- 20
- U.S. states
- 14
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Cancer Center | Tucson | Arizona | 85724 | — |
| Pacific Coast Hematology Oncology Group | Fountain Valley | California | 92708 | — |
| Pasco Hernando Oncology | New Port Richey | Florida | 34652 | — |
| Rush University Medical Center | Chicago | Illinois | 60612 | — |
| The University of Chicago | Chicago | Illinois | 60637 | — |
| University of Maryland, Greenebaun Cancer Center | Baltimore | Maryland | 21201 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02115 | — |
| Nebraska Medical Center | Omaha | Nebraska | 68198 | — |
| Nevada Cancer Research Foundation | Las Vegas | Nevada | 89106 | — |
| VA Sierra Nevada Health Care System | Reno | Nevada | 89502 | — |
| New Mexico Oncology Hematology Consultants | Albuquerque | New Mexico | 87109 | — |
| Columbia Presbyterian Medical Center | New York | New York | 10032 | — |
| Penn State Milton S. Hershey Medical Center | Hershey | Pennsylvania | 17033 | — |
| University of Pittsburg Cancer Institute | Pittsburgh | Pennsylvania | 15232 | — |
| The Family Cancer Center | Collierville | Tennessee | 38017 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | — |
| Southwest Regional Cancer Center | Austin | Texas | 78705 | — |
| Center for Oncology Research and Treatment | Dallas | Texas | 75230 | — |
| East Texas Medical Center | Tyler | Texas | 75701 | — |
| Danville Hematology Oncology | Danville | Virginia | 24541 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00372073, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 21, 2021 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00372073 live on ClinicalTrials.gov.